IP Library Granted Patent US 8,618,084
Granted Patent B2
US 8,618,084 · App. 12/937,534 · Granted Dec 31, 2013

Aldosterone induced vascular elastin production

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,618,084
App. No.
12/937,534
Granted
Dec 31, 2013
Kind
B2
Abstract

Compositions and methods for inducing the deposition of elastin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.

Claims (8)

1. A method for increasing the net deposition of elastin in a post-infarcted heart comprising:

administering an effective amount of the mineralocorticoid aldosterone, and an effective amount of the collagen inhibitor spironolactone to a subject in need thereof.

2. The method of claim 1 , wherein the mineralocorticoid is administered by a method selected from a group consisting of local administration and systemic administration.

3. The method of claim 1 , wherein the mineralocorticoid is administered by a mode selected from a group consisting of topical, parenteral, pleural infusion, pericardial infusion, subcutaneous, intravenous, intraperitoneal, transdermal, oral, buccal, inhalation, depot injection, and implantation.

4. The method of claim 1 , wherein the mineralocorticoid affects cardiac fibroblasts in a mineralocorticoid receptor-independent manner.

5. The method of claim 1 , wherein the collagen inhibitor is administered prior to the mineralocorticoid.

6. The method of claim 1 , wherein the collagen inhibitor is administered by a method selected from a group consisting of local administration and systemic administration.

7. The method of claim 1 , wherein the collagen inhibitor is administered by a mode selected from a group consisting of topical, parenteral, pleural infusion, pericardial infusion, subcutaneous, intravenous, intraperitoneal, transdermal, oral, buccal, inhalation, depot injection, and implantation.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2024
From: ELASTOGENESIS LLC
To: NULASTIN, INC.
Reel/Frame 068190/0171 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2024
From: THE HOSPITAL FOR SICK CHILDREN
To: ELASTOGENESIS LLC
Reel/Frame 067829/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2019
From: HUMAN MATRIX SCIENCES, LLC
To: ELASTOGENESIS, LLC
Reel/Frame 048891/0950 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2010
From: MITTS, THOMAS F.
To: HUMAN MATRIX SCIENCES, LLC
Reel/Frame 025236/0429 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2010
From: MITTS, THOMAS F.
To: HUMAN MATRIX SCIENCES, LLC
Reel/Frame 025236/0539 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2010
From: HINEK, ALEKSANDER
To: THE HOSPITAL FOR SICK CHILDREN
Reel/Frame 025236/0561 →